dasselta
krka, d.d., novo mesto - desloratadinas - rhinitis, allergic, perennial; rhinitis, allergic, seasonal; urticaria - antihistamininiai vaistai sisteminio naudojimo, - dasselta yra nurodytas atleidimo iš simptomų, susijusių su:alerginiu rinitu;dilgėlinė.
desloratadine fiterman
niromed, uab - desloratadinas - geriamasis tirpalas - 0,5 mg/ml - desloratadine
adcirca (previously tadalafil lilly)
eli lilly nederland b.v. - tadalafilis - hipertenzija, plaučių vėžys - urologiniai preparatai - adultstreatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity (see section 5. veiksmingumas buvo nustatytas idiopatinių pah (ipah) ir pah, susijusių su kolageno kraujagyslių ligomis. paediatric populationtreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (pah) classified as who functional class ii and iii.
tadalafil zentiva
zentiva k.s. - tadalafilis - plėvele dengtos tabletės - 5 mg - tadalafil
tadalafil zentiva
zentiva k.s. - tadalafilis - plėvele dengtos tabletės - 20 mg - tadalafil
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klopidogrelio hidrochloridas - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitromboziniai vaistai - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
rivaroxaban g.l. pharma
g.l. pharma gmbh - rivaroksabanas - plėvele dengtos tabletės - 10 mg - rivaroxaban
rivaroxaban g.l. pharma
g.l. pharma gmbh - rivaroksabanas - plėvele dengtos tabletės - 15 mg - rivaroxaban
rivaroxaban g.l. pharma
g.l. pharma gmbh - rivaroksabanas - plėvele dengtos tabletės - 20 mg - rivaroxaban
sunitinib g.l. pharma
g.l. pharma gmbh - sunitinibas - kietosios kapsulės - 12,5 mg - sunitinib